Two Phase 3 Trials Challenge Chemotherapy in Frontline NSCLC

Published Date: 05 Jun 2026

Phase 3 data on sunvozertinib for EGFR exon 20 insertions and sacituzumab tirumotecan plus pembrolizumab for PD-L1-positive disease show significant PFS gains over current standards.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

2.

Is global cancer care losing its human touch?

3.

New study links air pollution with higher rates of head and neck cancer

4.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

5.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot